SNOA - Sonoma Pharmaceuticals, Inc.

2.606
-0.194   -7.444%

Share volume: 47,098
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$2.80
-0.19
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
19%
Profitability 25%
Dept financing 8%
Liquidity 66%
Performance 4%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.24%
1 Month
-13.99%
3 Months
-25.65%
6 Months
-42.98%
1 Year
21.78%
2 Year
1,583.46%
Key data
Stock price
$2.61
P/E Ratio 
0.00
DAY RANGE
$2.45 - $2.77
EPS 
-$2.19
52 WEEK RANGE
$1.75 - $6.92
52 WEEK CHANGE
$30.95
MARKET CAP 
6.192 M
YIELD 
N/A
SHARES OUTSTANDING 
1.731 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
06-16-2025
BETA 
2.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$12,073
AVERAGE 30 VOLUME 
$17,402
Company detail
CEO: Amy M. Trombly
Region: US
Website: sonomapharma.com
Employees: 180
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses. It also offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites.

Recent news